Area of research
Oncology · Radiology, Nuclear Medicine and Imaging
Research interest
Joan Brugge , Ph.D., received her Ph.D. in virology from Baylor College of Medicine, and was a postdoctoral researcher at the University of Colorado Medical Center. After professorships at SUNY, Stony Brook and the University of Pennsylvania, where she was an HHMI investigator, she became the Scientific Director and Senior VP at ARIAD Pharmaceuticals. She returned to academia as Professor of Cell Biology at HMS in 1997, and was Chair of the department from 2004-2014. She became Co-Director of the Ludwig Center at Harvard in 2014. She currently sits on the Scientific Advisory Board of the Allen Institute of Cell Sciences.
Defining breast epithelial cell types in the single-cell era
Abstract 7152: High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlatives of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer
92 High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlatives of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer
Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
A human breast atlas integrating single-cell proteomics and transcriptomics
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
Cycling cancer persister cells arise from lineages with distinct programs
Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids
Clonal populations of a human TNBC model display significant functional heterogeneity and divergent growth dynamics in distinct contexts
Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages
Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer
Abstract P4-07-01: Tumor expression and microenvironment in HER2-positive breast cancer before and on HER2-targeted therapy: Analysis of microarray expression data from the TRIO-US B07 trial
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference
Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in <i>RAS</i> mutant cancers
Akt regulation of glycolysis mediates bioenergetic stability in epithelial cells
Rapid Sequential <i>in Situ</i> Multiplexing With DNA-Exchange-Imaging
Differential Glutamate Metabolism in Proliferating and Quiescent Mammary Epithelial Cells
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics
ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP
Cytokinesis involves a nontranscriptional function of the Hippo pathway effector YAP
Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours
Oncogene-like induction of cellular invasion from centrosome amplification
Mesenchymal gene program–expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance
Frequency-Modulated Pulses of ERK Activity Transmit Quantitative Proliferation Signals
Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
Substrate stiffness regulates cadherin-dependent collective migration through myosin-II contractility